A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral CR845 in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2019
Price : $35 *
At a glance
- Drugs Difelikefalin (Primary)
- Indications Pruritus
- Focus Therapeutic Use
- Sponsors Cara Therapeutics
- 05 Nov 2019 According to a Cara Therapeutics media release, the top-line data is expected in 2020.
- 12 Aug 2019 Status changed from not yet recruiting to recruiting.
- 23 Jul 2019 Planned initiation date changed from 1 Jun 2019 to 1 Jul 2019.